Astria治疗器接受FDA为Navenibart指定用于治疗遗传血管血肿的孤儿药品。 Astria Therapeutics receives FDA Orphan Drug Designation for navenibart to treat hereditary angioedema.

Astria治疗疗法已经获得FDA的Navenibart孤儿药物指认,目的是治疗遗传血管血肿,这是一种罕见的遗传病,引起严重的组织肿胀。 Astria Therapeutics has obtained FDA Orphan Drug Designation for navenibart, aimed at treating hereditary angioedema, a rare genetic disorder causing severe tissue swelling. 这一指定有利于发展,并提供扩大的营销独家经营。 This designation facilitates development and offers extended marketing exclusivity. 第1b/2阶段的研究结果表明,在六个月内,袭击率下降了90-96%。 Phase 1b/2 study results indicated a 90-96% reduction in attack rates over six months. 该公司计划在今年晚些时候发布更多的数据,并在2025年初启动第三阶段试验。 The company plans to release more data later this year and initiate a Phase 3 trial in early 2025.

文章

Market Screener

Morningstar

Market Screener

-- 显示更少 --

延伸阅读

相关故事